CASIRIVIMAB+IMDEVIMAB
About CASIRIVIMAB+IMDEVIMAB
CASIRIVIMAB+IMDEVIMAB belongs to the group of monoclonal antibodies used in the post-exposure treatment of mild to moderate respiratory illness caused by COVID-19 in people aged 12 years or older, weighing at least 40kgs. CASIRIVIMAB+IMDEVIMAB is used in non-hospitalised cases of COVID-19 that are at risk of progressing to severe disease.
CASIRIVIMAB+IMDEVIMAB contains Casirivimab and Imdevimab which work by using proteins (monoclonal antibodies) that mimic the natural immune system of the body and fight off the harmful virus. They block the virus attachment and entry into the human cells, thereby preventing the progression of the illness.
A qualified healthcare professional will administer CASIRIVIMAB+IMDEVIMAB. Do not self-administer. CASIRIVIMAB+IMDEVIMAB may cause certain common side effects such as redness, pain and soreness at the injection site. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if these side effects persist.
It is advisable to inform the doctor if you are allergic to any of its components. Consult your doctor if you are pregnant, planning to get pregnant or are breastfeeding. CASIRIVIMAB+IMDEVIMAB is not authorized for use in patients who require oxygen therapy or hospitalisation due to COVID-19.
Uses of CASIRIVIMAB+IMDEVIMAB
Medicinal Benefits
CASIRIVIMAB+IMDEVIMAB contains monoclonal antibodies used in the post-exposure treatment of mild to moderate disease caused by SARS-CoV-2. CASIRIVIMAB+IMDEVIMAB works by using monoclonal proteins to imitate the natural defence mechanism of the body. The COVID virus contains a capsid with spike proteins, through which it penetrates into the body cells to cause infection. CASIRIVIMAB+IMDEVIMAB binds to the spike protein of the virus. Thereby blocking the spike protein of the virus from attaching to the human receptor cell and arresting the progress of the disease. Hence, CASIRIVIMAB+IMDEVIMAB finds use in preventing the progression of mild to moderate covid cases to severe cases requiring hospitalisation. Thus, CASIRIVIMAB+IMDEVIMAB finds use in reducing rates of hospitalisation. CASIRIVIMAB+IMDEVIMAB may also be used as post-exposure prophylaxis of coronavirus disease in people who are not fully vaccinated against COVID-19, people with immunocompromising conditions, and in those who are at high risk of being exposed to someone with COVID-19.
Directions for Use
Storage
Side Effects of CASIRIVIMAB+IMDEVIMAB
- Redness, soreness and pain at the injection site
Patients Concern
Disease/Condition Glossary
Coronavirus Disease: Coronavirus disease is an infection caused by the SARS-CoV-2 virus. It can range from a mild cold, cough and fever to full-blown pneumonia. Coronavirus belongs to a group of RNA viruses and has crown-like projections on the surface of the pathogen. The virus transmits through droplets generated from an infectious person’s cough, sneeze or heavy breathing. The common symptoms of coronavirus disease are dry cough, tiredness, breathlessness, fever, loss of sense of taste and smell, diarrhoea, body pains, headache, and sore throat.
FAQs
CASIRIVIMAB+IMDEVIMAB works by inducing an antibody response in the body by instilling monoclonal antibodies that mimic the natural defences of the body and block the spike protein of the virus from attaching to body cells, thus arresting the progression of the disease.
Advanced age, obesity, chronic kidney disease, lung disease, sickle cell disease, neurodevelopmental disorders (for example cerebral palsy) and diseases of metabolism are high-risk factors for disease progression.
Not enough literature exists to ascertain the effects of CASIRIVIMAB+IMDEVIMAB on fertility. Please consult your doctor in case of any concerns.
Covid-19 spreads through respiratory droplets when in close or direct contact with an infected person. The virus can spread through an infected person’s sneeze or cough. The virus can also be transmitted by touching any contaminated surfaces and then touching the nose, mouth or eyes without washing the hands.
Vaccines stimulate the body to make its own antibodies against infection. On the other hand, monoclonal antibodies deliver lab-made antibodies against the virus.
Available Medicines for
CASIRIVIMAB+IMDEVIMAB
Ronapreve 120 mg/ml Injection 2's (2 Vials Combipack)
1 Combipack
₹97990 (MRP 119500)18%Off
cashback: 0
Casirivimab / Imdevimab Combo Pack 2400 mg (Regn-COV2) Injection 1's
1 Combipack
₹97990 (MRP 119500)18%Off
cashback: 0